Skip to main content
Top
Published in: Current Nutrition Reports 1/2016

01-03-2016 | Cancer (MF Leitzmann, Section Editor)

Obesity in Relation to Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus

Authors: Aaron P. Thrift, Bradley J. Kendall

Published in: Current Nutrition Reports | Issue 1/2016

Login to get access

Abstract

The incidence of esophageal adenocarcinoma has increased rapidly in the USA and other western populations. Barrett’s esophagus, a metaplastic change in the distal esophagus, is the only known precursor for esophageal adenocarcinoma. Epidemiological studies strongly implicate gastroesophageal reflux disease symptoms and obesity as the primary causal factors for esophageal adenocarcinoma and Barrett’s esophagus. Recent studies suggest that abdominal obesity, rather than overall obesity, is associated with esophageal adenocarcinoma and Barrett’s esophagus and that these associations are not entirely explained by gastroesophageal reflux disease symptoms. Evidence from these studies indicates that abdominal obesity has both mechanical (for example, via disruption of the gastroesophageal junction and resulting gastroesophageal reflux symptoms) and nonmechanical metabolic and inflammatory effects on esophageal adenocarcinoma and Barrett’s esophagus. Overall, the current body of literature provides some insights into the potential biological mechanisms linking abdominal obesity with esophageal adenocarcinoma and Barrett’s esophagus.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide. IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide. IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2013. Available from: http://​globocan.​iarc.​fr.
2.
3.
go back to reference Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–6.CrossRefPubMed Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–6.CrossRefPubMed
4.
go back to reference Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23(12):3155–62.CrossRefPubMed Thrift AP, Whiteman DC. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol. 2012;23(12):3155–62.CrossRefPubMed
5.
go back to reference Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus. 2007;20(1):36–41.CrossRefPubMed Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus. 2007;20(1):36–41.CrossRefPubMed
6.
go back to reference Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.CrossRefPubMed Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.CrossRefPubMed
7.
go back to reference Kendall BJ, Whiteman DC. Temporal changes in the endoscopic frequency of new cases of Barrett’s esophagus in an Australian health region. Am J Gastroenterol. 2006;101(6):1178–82.CrossRefPubMed Kendall BJ, Whiteman DC. Temporal changes in the endoscopic frequency of new cases of Barrett’s esophagus in an Australian health region. Am J Gastroenterol. 2006;101(6):1178–82.CrossRefPubMed
8.
go back to reference Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, et al. Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994–2006. Gut. 2009;58(2):182–8.CrossRefPubMedPubMedCentral Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, et al. Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994–2006. Gut. 2009;58(2):182–8.CrossRefPubMedPubMedCentral
9.
go back to reference Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident Barrett’s oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol. 2007;42(1):17–22.CrossRefPubMed Post PN, Siersema PD, Van Dekken H. Rising incidence of clinically evident Barrett’s oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol. 2007;42(1):17–22.CrossRefPubMed
10.
go back to reference Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101(5):855–9.CrossRefPubMedPubMedCentral Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Br J Cancer. 2009;101(5):855–9.CrossRefPubMedPubMedCentral
11.
go back to reference Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162(11):1050–61.CrossRefPubMed Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett’s esophagus, erosive reflux disease, and nonerosive reflux disease. Am J Epidemiol. 2005;162(11):1050–61.CrossRefPubMed
12.
go back to reference Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.CrossRefPubMed Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–31.CrossRefPubMed
13.
go back to reference Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). PLoS One. 2014;9(7):e103508.CrossRefPubMedPubMedCentral Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). PLoS One. 2014;9(7):e103508.CrossRefPubMedPubMedCentral
14.
go back to reference Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett’s esophagus. Am J Gastroenterol. 2013;108(6):915–22.CrossRefPubMedPubMedCentral Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett’s esophagus. Am J Gastroenterol. 2013;108(6):915–22.CrossRefPubMedPubMedCentral
15.••
go back to reference Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1399–412. This article is the latest meta-analysis on the topic. It shows that abdominal obesity, independent of body mass index, is positively associated with Barrett’s esophagus and esophageal adenocarcinoma.CrossRefPubMed Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(11):1399–412. This article is the latest meta-analysis on the topic. It shows that abdominal obesity, independent of body mass index, is positively associated with Barrett’s esophagus and esophageal adenocarcinoma.CrossRefPubMed
16.
go back to reference Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2450–6.CrossRefPubMedPubMedCentral Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, et al. The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2450–6.CrossRefPubMedPubMedCentral
17.
go back to reference Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragones N, et al. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol. 2014;109(3):336–43.CrossRefPubMed Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragones N, et al. Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands. Am J Gastroenterol. 2014;109(3):336–43.CrossRefPubMed
18.••
go back to reference Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, et al. The role of gastroesophageal reflux and other factors during progression to esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2015;24(7):1012–23. This article shows that obesity may account for a large proportion of the increase in incidence of esophageal adenocarcinoma in the United States.CrossRefPubMed Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, et al. The role of gastroesophageal reflux and other factors during progression to esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2015;24(7):1012–23. This article shows that obesity may account for a large proportion of the increase in incidence of esophageal adenocarcinoma in the United States.CrossRefPubMed
19.
go back to reference Adams RJ, Appleton S, Wilson DH, Taylor AW, Dal Grande E, Chittleborough C, et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care. 2005;28(11):2777–9.CrossRefPubMed Adams RJ, Appleton S, Wilson DH, Taylor AW, Dal Grande E, Chittleborough C, et al. Population comparison of two clinical approaches to the metabolic syndrome: implications of the new International Diabetes Federation consensus definition. Diabetes Care. 2005;28(11):2777–9.CrossRefPubMed
20.
go back to reference Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia. 2007;50(6):1127–39.CrossRefPubMed Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia. 2007;50(6):1127–39.CrossRefPubMed
21.
go back to reference Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut. 2008;57(2):173–80.CrossRefPubMed Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut. 2008;57(2):173–80.CrossRefPubMed
22.
go back to reference World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1–253. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1–253.
23.
go back to reference Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr. 1998;68(4):899–917. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr. 1998;68(4):899–917.
24.
go back to reference Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012;41(6):1706–18.CrossRefPubMedPubMedCentral Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012;41(6):1706–18.CrossRefPubMedPubMedCentral
25.•
go back to reference Steffen A, Huerta JM, Weiderpass E, Bueno-de-Mesquita HB, May AM, Siersema PD, et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015;137(3):646–57. This article shows that abdominal obesity, rather than total obesity, is associated with increased risk of esophageal adenocarcinoma.CrossRefPubMed Steffen A, Huerta JM, Weiderpass E, Bueno-de-Mesquita HB, May AM, Siersema PD, et al. General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015;137(3):646–57. This article shows that abdominal obesity, rather than total obesity, is associated with increased risk of esophageal adenocarcinoma.CrossRefPubMed
26.
go back to reference Lindkvist B, Johansen D, Stocks T, Concin H, Bjorge T, Almquist M, et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer. 2014;14:103.CrossRefPubMedPubMedCentral Lindkvist B, Johansen D, Stocks T, Concin H, Bjorge T, Almquist M, et al. Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer. 2014;14:103.CrossRefPubMedPubMedCentral
27.
go back to reference Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013;24(3):609–17.CrossRefPubMed Turati F, Tramacere I, La Vecchia C, Negri E. A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013;24(3):609–17.CrossRefPubMed
28.
go back to reference Cook MB, Freedman ND, Gamborg M, Sorensen TI, Baker JL. Childhood body mass index in relation to future risk of oesophageal adenocarcinoma. Br J Cancer. 2015;112(3):601–7.CrossRefPubMedPubMedCentral Cook MB, Freedman ND, Gamborg M, Sorensen TI, Baker JL. Childhood body mass index in relation to future risk of oesophageal adenocarcinoma. Br J Cancer. 2015;112(3):601–7.CrossRefPubMedPubMedCentral
29.
go back to reference Levi Z, Kark JD, Shamiss A, Derazne E, Tzur D, Keinan-Boker L, et al. Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. Cancer. 2013;119(23):4086–93.CrossRefPubMed Levi Z, Kark JD, Shamiss A, Derazne E, Tzur D, Keinan-Boker L, et al. Body mass index and socioeconomic status measured in adolescence, country of origin, and the incidence of gastroesophageal adenocarcinoma in a cohort of 1 million men. Cancer. 2013;119(23):4086–93.CrossRefPubMed
30.•
go back to reference Thrift AP, Shaheen NJ, Gammon MD, Bernstein L, Reid BJ, Onstad L, et al. Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014;106(11). pii: dju252. This article provides the strongest evidence yet that obesity is associated with Barrett’s esophagus and esophageal adenocarcinoma independently of gastroesophageal reflux symptoms. Thrift AP, Shaheen NJ, Gammon MD, Bernstein L, Reid BJ, Onstad L, et al. Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. J Natl Cancer Inst. 2014;106(11). pii: dju252. This article provides the strongest evidence yet that obesity is associated with Barrett’s esophagus and esophageal adenocarcinoma independently of gastroesophageal reflux symptoms.
31.
go back to reference Kubo A, Cook MB, Shaheen NJ, Vaughan TL, Whiteman DC, Murray L, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: a pooled analysis from the international BEACON consortium. Gut. 2013;62(12):1684–91.CrossRefPubMed Kubo A, Cook MB, Shaheen NJ, Vaughan TL, Whiteman DC, Murray L, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett’s oesophagus: a pooled analysis from the international BEACON consortium. Gut. 2013;62(12):1684–91.CrossRefPubMed
32.
go back to reference Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gomez J, et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr. 2004;23(6):1430–53.CrossRefPubMed Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Manuel Gomez J, et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr. 2004;23(6):1430–53.CrossRefPubMed
33.
go back to reference Thrift AP, Kramer JR, Alsarraj A, El-Serag HB. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014;48(3):218–23.CrossRefPubMedPubMedCentral Thrift AP, Kramer JR, Alsarraj A, El-Serag HB. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol. 2014;48(3):218–23.CrossRefPubMedPubMedCentral
34.
go back to reference Kendall BJ, Macdonald GA, Prins JB, O’Brien S, Whiteman DC. Total body fat and the risk of Barrett’s oesophagus—a bioelectrical impedance study. Cancer Epidemiol. 2014;38(3):266–72.CrossRefPubMedPubMedCentral Kendall BJ, Macdonald GA, Prins JB, O’Brien S, Whiteman DC. Total body fat and the risk of Barrett’s oesophagus—a bioelectrical impedance study. Cancer Epidemiol. 2014;38(3):266–72.CrossRefPubMedPubMedCentral
36.
go back to reference El-Serag HB, Hashmi A, Garcia J, Richardson P, Alsarraj A, Fitzgerald S, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case-control study. Gut. 2014;63(2):220–9.PubMedPubMedCentral El-Serag HB, Hashmi A, Garcia J, Richardson P, Alsarraj A, Fitzgerald S, et al. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case-control study. Gut. 2014;63(2):220–9.PubMedPubMedCentral
38.
39.
go back to reference Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639–49.CrossRefPubMed Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639–49.CrossRefPubMed
40.
go back to reference Robertson EV, Derakhshan MH, Wirz AA, Lee YY, Seenan JP, Ballantyne SA, et al. Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology. 2013;145(4):730–9.CrossRefPubMed Robertson EV, Derakhshan MH, Wirz AA, Lee YY, Seenan JP, Ballantyne SA, et al. Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology. 2013;145(4):730–9.CrossRefPubMed
41.
go back to reference Wu JC, Mui LM, Cheung CM, Chan Y, Sung JJ. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology. 2007;132(3):883–9.CrossRefPubMed Wu JC, Mui LM, Cheung CM, Chan Y, Sung JJ. Obesity is associated with increased transient lower esophageal sphincter relaxation. Gastroenterology. 2007;132(3):883–9.CrossRefPubMed
42.
go back to reference Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–56.CrossRefPubMed Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89(6):2548–56.CrossRefPubMed
44.
go back to reference Lago F, Dieguez C, Gomez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 2007;3(12):716–24.CrossRefPubMed Lago F, Dieguez C, Gomez-Reino J, Gualillo O. Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 2007;3(12):716–24.CrossRefPubMed
45.
go back to reference Thomas EL, Parkinson JR, Frost GS, Goldstone AP, Dore CJ, McCarthy JP, et al. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring). 2012;20(1):76–87.CrossRef Thomas EL, Parkinson JR, Frost GS, Goldstone AP, Dore CJ, McCarthy JP, et al. The missing risk: MRI and MRS phenotyping of abdominal adiposity and ectopic fat. Obesity (Silver Spring). 2012;20(1):76–87.CrossRef
46.
go back to reference Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care. 2005;28(9):2322–5.CrossRefPubMed Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diabetes Care. 2005;28(9):2322–5.CrossRefPubMed
47.
50.
go back to reference Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190(5):562–72.CrossRefPubMed Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg. 2000;190(5):562–72.CrossRefPubMed
51.
go back to reference Almers LM, Graham JE, Havel PJ, Corley DA. Adiponectin may modify the risk of Barrett’s esophagus in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2015. Almers LM, Graham JE, Havel PJ, Corley DA. Adiponectin may modify the risk of Barrett’s esophagus in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2015.
52.
go back to reference Garcia JM, Splenser AE, Kramer J, Alsarraj A, Fitzgerald S, Ramsey D, et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett’s esophagus: a case-control study. Clin Gastroenterol Hepatol. 2014;12(2):229–38.CrossRefPubMedPubMedCentral Garcia JM, Splenser AE, Kramer J, Alsarraj A, Fitzgerald S, Ramsey D, et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett’s esophagus: a case-control study. Clin Gastroenterol Hepatol. 2014;12(2):229–38.CrossRefPubMedPubMedCentral
53.
go back to reference Greer KB, Thompson CL, Brenner L, Bednarchik B, Dawson D, Willis J, et al. Association of insulin and insulin-like growth factors with Barrett’s oesophagus. Gut. 2012;61(5):665–72.CrossRefPubMedPubMedCentral Greer KB, Thompson CL, Brenner L, Bednarchik B, Dawson D, Willis J, et al. Association of insulin and insulin-like growth factors with Barrett’s oesophagus. Gut. 2012;61(5):665–72.CrossRefPubMedPubMedCentral
54.
go back to reference Greer KB, Falk GW, Bednarchik B, Li L, Chak A. Associations of serum adiponectin and leptin with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2015. Greer KB, Falk GW, Bednarchik B, Li L, Chak A. Associations of serum adiponectin and leptin with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2015.
55.
go back to reference Rubenstein JH, Morgenstern H, McConell D, Scheiman JM, Schoenfeld P, Appelman H, et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett’s esophagus. Gastroenterology. 2013;145(6):1237–44.CrossRefPubMedPubMedCentral Rubenstein JH, Morgenstern H, McConell D, Scheiman JM, Schoenfeld P, Appelman H, et al. Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett’s esophagus. Gastroenterology. 2013;145(6):1237–44.CrossRefPubMedPubMedCentral
56.••
go back to reference Chandar AK, Devanna S, Lu C, Singh S, Greer K, Chak A, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015. [Epub ahead of print] This article shows that the positive association between abdominal obesity and Barrett’s esophagus may be mediated by insulin and leptin. Chandar AK, Devanna S, Lu C, Singh S, Greer K, Chak A, et al. Association of serum levels of adipokines and insulin with risk of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015. [Epub ahead of print] This article shows that the positive association between abdominal obesity and Barrett’s esophagus may be mediated by insulin and leptin.
57.
go back to reference Iyer PG, Borah BJ, Heien HC, Das A, Cooper GS, Chak A. Association of Barrett’s esophagus with type II Diabetes Mellitus: results from a large population-based case-control study. Clin Gastroenterol Hepatol. 2013;11(9):1108–14.CrossRefPubMed Iyer PG, Borah BJ, Heien HC, Das A, Cooper GS, Chak A. Association of Barrett’s esophagus with type II Diabetes Mellitus: results from a large population-based case-control study. Clin Gastroenterol Hepatol. 2013;11(9):1108–14.CrossRefPubMed
58.
go back to reference Drahos J, Ricker W, Parsons R, Pfeiffer RM, Warren JL, Cook MB. Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-Medicare Data. J Clin Gastroenterol. 2015;49(4):282–8.CrossRefPubMed Drahos J, Ricker W, Parsons R, Pfeiffer RM, Warren JL, Cook MB. Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-Medicare Data. J Clin Gastroenterol. 2015;49(4):282–8.CrossRefPubMed
59.
go back to reference Thrift AP, Hilal J, El-Serag HB. Metabolic syndrome and the risk of Barrett’s oesophagus in white males. Aliment Pharmacol Ther. 2015;41(11):1182–9.CrossRefPubMed Thrift AP, Hilal J, El-Serag HB. Metabolic syndrome and the risk of Barrett’s oesophagus in white males. Aliment Pharmacol Ther. 2015;41(11):1182–9.CrossRefPubMed
60.
go back to reference Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970–6.CrossRefPubMed Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61(7):970–6.CrossRefPubMed
61.
go back to reference Hardikar S, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL. The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett’s esophagus. PLoS One. 2013;8(1):e52192.CrossRefPubMedPubMedCentral Hardikar S, Onstad L, Blount PL, Odze RD, Reid BJ, Vaughan TL. The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett’s esophagus. PLoS One. 2013;8(1):e52192.CrossRefPubMedPubMedCentral
Metadata
Title
Obesity in Relation to Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus
Authors
Aaron P. Thrift
Bradley J. Kendall
Publication date
01-03-2016
Publisher
Springer US
Published in
Current Nutrition Reports / Issue 1/2016
Electronic ISSN: 2161-3311
DOI
https://doi.org/10.1007/s13668-016-0151-0

Other articles of this Issue 1/2016

Current Nutrition Reports 1/2016 Go to the issue

Dietary Patterns and Behavior (LM Steffen, Section Editor)

The Relationship Between Food Insecurity, Dietary Patterns, and Obesity

Cancer (MF Leitzmann, Section Editor)

Adolescent Diet and Breast Cancer Risk